Hosted on MSN11mon
Gilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma assetKite, a division of Gilead Sciences (NASDAQ:GILD), and Arcellx (NASDAQ:ACLX) will begin a phase 3 study of their CAR-T multiple myeloma treatment anitocabtagene autoleucel (anito-cel) in the H2 ...
The university’s expertise in wind engineering is being tapped to revolutionize the high-performance kite industry at a time ...
From flying a simple single-line kite to participating in full-on "kite battles," the tradition of kite-flying is a pastime ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results